Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the colon or rectum~* Metastatic or recurrent disease that is not amenable to potentially curative treatment~* Progressive or recurrent disease during or after 1, and only 1, regimen of fluorouracil with or without leucovorin calcium or during or within 6 months after adjuvant chemotherapy with fluorouracil and leucovorin calcium~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 50-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT/SGPT no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)~* Alkaline phosphatase no greater than 2 times ULN (no greater than 5 times ULN if liver metastases present)~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No unstable angina~* No New York Heart Association class III or IV congestive heart failure~* No serious cardiac arrhythmia~* No history of cardiac toxicity from fluorouracil/leucovorin calcium~* No myocardial infarction within past 6 months~Pulmonary:~* No interstitial pneumonia or extensive and symptomatic fibrosis of the lung~Other:~* No uncontrolled predisposing colonic or small bowel disorder~* No prior chronic enteropathy, chronic diarrhea, or unresolved bowel obstruction/subobstruction~* No diabetes~* No active infection~* No known current peripheral neuropathy~* No concurrent active cancer except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix~* No intolerance of appropriate antiemetics~* No history of anaphylaxis or potential intolerance to atropine sulfate or loperamide~* Not pregnant or nursing~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy~* No prior irinotecan or oxaliplatin~* No other prior chemotherapy agents except fluorouracil with or without leucovorin calcium as first-line therapy for metastatic disease or in the adjuvant setting~Endocrine therapy:~* Not specified~Radiotherapy:~* Prior radiotherapy to non-target lesions allowed~* No prior radiotherapy to target lesions unless disease progression is documented within the radiation port~* At least 3 weeks since prior radiotherapy~Surgery:~* At least 4 weeks since prior major surgical procedure and recovered~* Prior surgery for primary tumor or metastasis allowed~Other:~* At least 30 days since prior investigational drug~* No concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete